| Biomarker ID | 139 |
| PMID | 17459658 |
| Year | 2007 |
| Biomarker | CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased GEX Score with relapse |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (UBE2C): Inactivation of APC/C via direct inhibition of the APC/C complex, Autodegradation of Cdh1 by Cdh1-APC/C, APC/C-mediated degradation of cell cycle proteins, Cell cycle checkpoints, Interleukin-1 signaling pathway |
| Experiment | Relapse Vs No Relapse |
| Type of Biomarker | Prognostic |
| Cohort | 71 patients with Prostate Cancer were included. 55 of them did not relapse and 16 did. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.73 |
| Accuracy | NA |
| Level Of Significance | p=0.007 |
| Method Used | array based DASL |
| Clinical | No |
| Remarks | 16 genes combined together to form GEX score. For all the selected genes, we fitted linear models (using the rlm function with method “MM†in the MASS library of the R statistical package) to predict Gleason grades and used the average of 16 independently derived predicted values, GEX, as a gene expression analogy of the Gleason grade. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, DTL, UBE2C, WNT5A, ALCAM, AZGP1, CCK, MYLK, PLPP3, PROK1 |